NXC736
Phase 2Small molecule
NXC736 is one of 39 small molecule programs targeting Alopecia Areata. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
113 competitors in Alopecia Areata
#DrugCompanyPhaseTrials
1Opzelura
PfizerPhase 3
Olumiant
Eli LillyPhase 3
Rinvoq
AbbViePhase 3
PF-06651600
PfizerPhase 3
Orencia
Bristol-Myers SquibbPhase 2
Jaktinib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
Jakafi
IncytePhase 2
SHR0302
RReistone Biopharma Company Limited
Phase 3
IL2
AAssistance Publique - Hôpitaux de Paris
Phase 3
Eucrisa
AAnacor
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NXC736. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNEXTGEN Bioscience